IL-15 Protein (AA 49-162)

N° du produit ABIN6386427

Protéine Recombinant IL-15 exprimée dans Escherichia coli (E. coli).

Aperçu rapide pour IL-15 Protein (AA 49-162) (ABIN6386427)

Antigène: IL-15 (IL15) (Interleukin 15 (IL15))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Humain

Source: Escherichia coli (E. coli)

Pureté: >95 % as determined by SDS-PAGE.

Détail du produit

Attributs du protein: AA 49-162

Séquence: AA 49-162

niveau d'endotoxine: Less than 0.1 EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: PBS, pH 7.4

Conseil sur la manipulation: Please avoid repeated freeze-thaw cycles.

Stock: -20 °C

Détail du antigène

Antigène: IL-15 (IL15) (Interleukin 15 (IL15))

Autre désignation: IL-15

Sujet: Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells, cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

Poids moléculaire: 12.8 kDa

Pathways: Signalistation JAK/STAT, Glycosaminoglycan Metabolic Process